[iito] Business Intelligence – The Elephants Are Coming 560x91px
Organisation › Details

Lytix Biopharma AS

Lytix Biopharma’s technology is based on nature’s own defense mechanisms. The membranes of cancer cells are destroyed. Our unique technology is a new class of cancer immunotherapy that activates the patient`s own immune system. Lytix Biopharma’s strategy is to develop its drug candidates to end Phase II, and then collaborate with partners for the final stages of product development and commercialization. *


Period Start 2013-11-28 existent
Products Industry cancer immunotherapy (immuno-oncology, I-O)
  Industry 2 LTX-315 (Lytix Biopharma)
Persons Person Wickholm, Håkan (Lytix Biopharma AS 201603– CEO)
  Person 2 Furuseth, Torbjørn (Targovax 201809– CFO before Lytix Biopharma + Aker Biomarine + Trygg Pharma + McKinsey)
Region Region Tromsø
  Country Norway
  City 2994 Tromsø
  Tel +47-77-675500
    Address record changed: 2013-11-28
Basic data Employees n. a.
    * Document for �About Section�: Lytix Biopharma AS. (12/15/15). "Press Release: Lytix Biopharma Raises Approximately 80 Million NOK".
Record changed: 2018-01-31


[iito] Business Intelligence – The Elephants Are Coming 560x91px

More documents for Lytix Biopharma AS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top